echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > JNNP: Risk of health defect accumulation, lipoprotein E genotype and late-onset cognitive impairment and dementia

    JNNP: Risk of health defect accumulation, lipoprotein E genotype and late-onset cognitive impairment and dementia

    • Last Update: 2020-12-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    A healthy lifestyle is associated with a reduced risk of developing dementia in later life.
    by examining the accumulation or measuring vulnerability of age-related health defects, we can also observe how overall health affects the risk of dementia.
    is an age-related health condition associated with an increased risk of adverse events, dementia and death.
    to measure the degree of weakness in each person may help identify those without cognitive impairment who are most likely to develop MILD cognitive impairment MCI.
    study whether the accumulation of APOE genotypes and health defects is independent of mild cognitive impairment (MCI) and the risk of dementia.
    : The data was provided by the Alzheimer's Disease Research Center (ADRC) across the United States.
    the debilitating index of Alzheimer's patients over the age of 50 using defect accumulation.
    cognitive status is determined through clinical evaluation.
    using a multi-state transition model, we assessed the extent to which increased weakness affects the probability of transition between non-cognitive impairment (NCI), MCI, and dementia.
    participants included people with MCI and Alzheimer's disease and related diseases, as well as some healthy volunteers.
    since 2005, these ADRCs have collected data through forward-looking, standardized and longitudinal clinical assessments of subjects, resulting in a unified data set (UDS).
    For UDS, baseline and follow-up data (approximately once a year) is collected by clinicians and clinic staff and contains indeterminate information about participants' sociodetics, neurological test results, functional status, neuropsychiatric test results, clinical diagnosis, and APOE genotype.
    results: The average age of the subjects (n-14,490) was 72.2 years (standard deviation: 8.9 years; range- 50-103 years).
    NCI at the baseline (n-9773), for every 0.1 increase in the weakness index, there is a higher risk of MCI occurrence and a higher risk of developing dementia.
    patients with MCI at the time of the baseline examination (n-4717), the higher the degree of weakness, the higher the risk of developing dementia, the lower the likelihood of being reclassified as NCI, and the higher the likelihood of reclassifying as NCI.
    these risk effects are present and similar in both carriers and non-carriers of the lipoprotein e-4 allegen.
    : Weakness is a key risk factor for cognitive dysfunction and dementia in old age, both as a goal of age-related cognitive impairment prevention interventions and as a possible prognostic marker for MCI patients.
    study supports the idea that late-onset dementia is a complex outcome of aging that is often associated with overall health and genetic risk factors.
    in older U.S., the cumulative effects of health defects on the likelihood of cognitive impairment and cognitive improvement are independent of the strong genetic risk factors for dementia.
    is an important risk factor for cognitive dysfunction and a sign of potential prognostion value.
    Ward DD, Wallace LMK, Rockwood K K Health Health Financials, APOE genotype, and risk for later-life mild images and dementia Journal of Neurology, Neurosurgery and Psymy Published Online: 13 November 2020. doi:10.1136/jnnp-2020-324081MedSci Original Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mets Medicine and are not authorized to be reproduced by any media, website or individual , the authorization should be reproduced with the note "Source: Metz Medicine".
    all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
    at the same time reproduced content does not represent the position of this site.
    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.